» Articles » PMID: 31744428

Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia

Overview
Journal Psychiatr Serv
Specialty Psychiatry
Date 2019 Nov 21
PMID 31744428
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This cross-sectional study examined the relationship between antipsychotic medication adherence and preventable diabetes-related hospitalizations for individuals with diabetes and schizophrenia.

Methods: Hospitalizations related to diabetes, an ambulatory care sensitive condition, were assessed among Medicaid recipients in New York State with comorbid diabetes and schizophrenia (N=14,365) for three levels of antipsychotic medication adherence: very low to no engagement (two or fewer prescriptions or none in first 6 months), moderate to low adherence, and adherent (proportion of days covered ≥80%).

Results: Rates of preventable diabetes hospitalization were highest among individuals with very low to no engagement in antipsychotic treatment (4.7%), followed by those with moderate to low adherence (3.3%). Diabetes hospitalizations among adherent individuals were comparable with those of the total diabetes population (both 2.0%). The odds of a preventable diabetes hospitalization were significantly higher among individuals with very low to no engagement in antipsychotic treatment (adjusted odds ratio [AOR]=2.42) and among those with moderate to low adherence (AOR=1.57) than among adherent individuals. Black individuals were also at increased risk of a preventable diabetes hospitalization after the analyses adjusted for antipsychotic adherence and other variables (AOR=1.38).

Conclusions: This study indicates a relationship between antipsychotic adherence and improved diabetes outcomes among individuals with schizophrenia. Engagement in mental health treatment may be a critical path toward improving health disparities for individuals with schizophrenia. Individuals with very low to no engagement were a particularly vulnerable group, and the exclusion of persons with less than two prescriptions from research and quality measures should be revisited.

Citing Articles

Effect of H2H management mode on blood sugar control and living ability in patients with schizophrenia and type 2 diabetes mellitus.

Yang L, Wang J, Han L, Hu Y, Si L, Shao X Am J Transl Res. 2023; 15(1):223-232.

PMID: 36777852 PMC: 9908448.


The impact of comorbid severe mental illness and common chronic physical health conditions on hospitalisation: A systematic review and meta-analysis.

Launders N, Dotsikas K, Marston L, Price G, Osborn D, Hayes J PLoS One. 2022; 17(8):e0272498.

PMID: 35980891 PMC: 9387848. DOI: 10.1371/journal.pone.0272498.


Risk Factor for Retreatment Episode on Admission Among TB Patients With Schizophrenia.

Wang H, Han C, Wang J, Zhang Y, Wang M Front Psychiatry. 2021; 12:793470.

PMID: 34955934 PMC: 8695840. DOI: 10.3389/fpsyt.2021.793470.


Public health interventions on prescription redemptions and secondary medication adherence among type 2 diabetes patients: systematic review and meta-analysis of randomized controlled trials.

Bekele B, Bogale B, Negash S, Tesfaye M, Getachew D, Weldekidan F J Diabetes Metab Disord. 2021; 20(2):1933-1956.

PMID: 34900834 PMC: 8630245. DOI: 10.1007/s40200-021-00878-0.


Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar.

Abdul Karim M, Al-Baz N, Ouanes S, Khalil A, Assar A, Alsiddiqi A BMC Psychiatry. 2021; 21(1):149.

PMID: 33706754 PMC: 7953779. DOI: 10.1186/s12888-021-03121-5.